Anti-infective monoclonal antibodies: perils and promise of development

Nature Reviews. Drug Discovery
Janice M Reichert, Matthew C Dewitz

Abstract

So far, most monoclonal antibodies have been developed for treating cancer or immunological diseases. However, the global spread of infections such as West Nile and corona viruses, and the need to address the potential threat of bioterrorism, has boosted public interest in, and government support of, counter-measures for infectious diseases. The attractive features of monoclonal antibodies, such as high specificity and effective recruitment of the immune system, would seem to make them excellent candidates as anti-infective agents. Here, we analyse trends in the development and approval of anti-infective monoclonal antibodies, and discuss factors that influence their success.

References

Sep 1, 1989·The Journal of Infectious Diseases·R F HectorJ E Pennington
Jan 30, 1993·Lancet·T J InglisR T Calvert
Jan 1, 1994·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·M B KhazaeliA F LoBuglio
Feb 7, 2001·JAMA : the Journal of the American Medical Association·D C AngusN MacIntyre
Sep 5, 2001·Nature Biotechnology·J M Reichert
May 22, 2004·Nature Reviews. Drug Discovery·Janice Reichert, Alex Pavolu
Jun 29, 2004·The Lancet Infectious Diseases·David A GarberMark B Feinberg
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Sep 10, 2005·Nature Biotechnology·Janice M ReichertMatthew C Dewitz

❮ Previous
Next ❯

Citations

Dec 29, 2009·Médecine sciences : M/S·Christine Klinguer-HamourAlain Beck
Oct 24, 2009·The Journal of Biological Chemistry·Boxu YanGerd R Kleemann
Apr 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Arturo Casadevall
Dec 5, 2008·Protein Engineering, Design & Selection : PEDS·J GabbardA R M Bradbury
Oct 13, 2011·MBio·Jorge L Benach
Feb 2, 2013·PloS One·Valeriy DomenyukChris W Diehnelt
Feb 1, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Janice M Reichert
Nov 6, 2007·Expert Opinion on Emerging Drugs·Jan ter Meulen
Mar 1, 2008·Expert Opinion on Drug Discovery·Andreas Baumann
Jul 28, 2015·Human Vaccines & Immunotherapeutics·Xiaomei GengYuanjia Hu
Jul 1, 2008·Current Opinion in Immunology·Patrick G SwannKathleen A Clouse
Dec 24, 2010·Vox Sanguinis·T Burnouf
May 20, 2008·Biochemical Pharmacology·S J EnnaM Williams
Feb 8, 2014·Human Vaccines & Immunotherapeutics·Xiangguo Qiu, Gary P Kobinger
Jan 14, 2010·MAbs·Sohini Mazumdar
Feb 3, 2007·Nature Reviews. Drug Discovery·Kathryn ChapmanIan Ragan
Mar 23, 2010·Nature Reviews. Drug Discovery·Trevor T HanselAndrew J T George
Sep 3, 2010·Nature Reviews. Drug Discovery·Aaron L NelsonJanice M Reichert
Jul 5, 2008·Expert Review of Molecular Diagnostics·Oswaldo Keith Okamoto, José Fernando Perez
Jul 24, 2012·Toxins·Siu-Kei Chow, Arturo Casadevall
Oct 18, 2020·Antibodies·Bruce A KeytMarvin S Peterson
Oct 17, 2020·Annual Review of Biophysics·Jiahui ChenGuo-Wei Wei

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

Clinical & Developmental Immunology
Roberto BurioniJ Donald Capra
Nursing
Kavitha S Dlal, Mary Barna Bridgeman
© 2021 Meta ULC. All rights reserved